Loss of Malignancy in Mouse Melanoma Cells by Long-Term Impact of Interferon-Beta In Vitro is Associated with N- and VE-Cadherins Suppression without Inhibition of Expression of EMT-Associated Twist and Slug Proteins
DOI:
https://doi.org/10.6000/1927-7229.2014.03.03.4Keywords:
Cadherins, anchorage-independent growth, changes of phenotype, tumorigenicity, metastasis.Abstract
Aim: To study the effect of long-term impact of mouse interferon-beta (IFN-b) on the behavior of mouse melanoma cells in vitro and in vivo and the expression of epithelial-mesenchymal transition (EMT) associated proteins.
Materials and Methods: Studies were performed on mouse B16 melanoma cells as a tumor model (MM-4 cell line). Immunocytochemical and tumor cell biology approaches have been used in this study.
Results: Long-time treatmentof MM-4 melanoma cellswith low-dose IFN-b (1/2 of IC50) leads to change their morphology, significant inhibition of cell growth and plating efficiency, suppression of cell migration and anchorage-independent growth in semisolid agar. Moreover, IFN-modification of melanoma cells is accompanied by the significant suppression of their malignancy in vivo: growth of tumor induced by IFN-treated cells has inhibited on 50% and growth of metastases - on 90%. Also, IFN-modification of MM-4 cells affects on the expression of proteins involved in cell cycle regulation and inhibits expression of some molecules of adhesion (N-, VE-cadherins), but not influence on the expression of EMT-associated Twist and Slug proteins and E-cadherin.
Conclusions: Long-term impact of mouse IFN-beta in low dose on melanoma cells in vitro changes their phenotype and inhibits their proliferative potential, signs of malignancy in vitro, tumorigenicity and metastatic ability in vivo. Loss of malignancy is associated with inhibition of N- and VE-cadherins expression, but not associated with the change of expression and subcellular localization of E-cadherin and EMT transcription factors Twist and Slug.
References
Verini C. Interferon therapy in malignant melanoma. U.S. Pharmacist [serial on the internet]. 10 Oct 1998; [cited 2014 February 20]; 23: [about 5 screens]. Available from: http://legacy.uspharmacist.com/oldformat.asp?url=newlook/files/feat/acf2fd3.cfm&pub_id=8&article_id=114.
Kirkwood JM, Ernstoff MS. Role of interferons in the therapy of melanoma. J Invest Dermatol 1990; 95: 180S-4S. http://dx.doi.org/10.1111/1523-1747.ep12875497
Tarhini AA, Gogas H, Kirkwood JM. IFN-alpha in the treatment of melanoma. J Immunol 2012; 189: 3789-93. http://dx.doi.org/10.4049/jimmunol.1290060
Alizadeh H, Howard K, Mellon J, et al. Reduction of liver metastasis of intraocular melanoma by interferon-? gene transfer. Invest Ophthalmol Vis Sci 2003; 44: 73042-51. http://dx.doi.org/10.1167/iovs.02-1147
Niederkorn JY. Immunology and immunomodulation of corneal transplantation. Intern Rev Immunol 2002; 21: 173-96. http://dx.doi.org/10.1080/08830180212064
Brassard DL, Grace MJ, Bordens RW. Interferon-? as an immunotherapeutic protein. J Leukoc Biol 2002; 71: 565-81.
Ismail A, Yusuf N. Type I interferons: key players in normal skin and select cutaneous malignancies. Dermatol Res Pract [serial on the internet]. 2014 Jen 5; [cited 2014 February 25]; 2014: [about 11 screens]. http://dx.doi.org/10.1155/2014/847545
L?pez-Ocejo O, Perea SE, Bequet-Romero M, et al. Impaired angiogenic balance and suppression of tumorigenicity in HeLa cells chronically exposed to interferon-alpha. Biochem Biophys Res Commun 2000; 277: 410-16. http://dx.doi.org/10.1006/bbrc.2000.3690
Garbe C, Krasagakis K, Zouboulis CC, et al. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol 1990; 95: 231S-37S. http://dx.doi.org/10.1111/1523-1747.ep12875837
Rozera C, Carlei D, Lollini PL, et al. Interferon (IFN)-? gene transfer into TS/A adenocarcinoma cells and comparison with IFN-?. Differential effects on tumorigenicity and host response. Am J Pathol 1999; 154: 1211-22. http://dx.doi.org/10.1016/S0002-9440(10)65373-4
Lykhova AA, Kudryavets YuI, Bezdenezhnykh NA, et al. Suppression of tumorigenicity and metastatic potential of melanoma cells by transduction of interferon-beta gene. Biopolym Cell 2014; 30: 61-7. http://dx.doi.org/10.7124/bc.00087F
Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884-93. http://dx.doi.org/10.1016/j.biochi.2007.04.006
Kudryavets YuI, Bezdenezhnykh NO, Lukyanova NYu, et al. Modifying influence of prolonged action of interferon on phenotypic characteristics of human lung cancer cells in vitro. Exp Oncol 2008; 30: 283-8.
Kovaleva OA, Bezdenezhnykh NO, Glazko TT, et al. Karyotype alterations in human lung adenocarcinoma cells after long-term action of interferon-alpha. Exp Oncol 2010; 32: 19-22.
Kudryavets YuI, Bezdenezhnykh NO, Lykhova OO, et al. The role of interferon as a modifier of epithelial-mesenchymal transition in tumor cells. Exp Oncol 2011; 33: 178-81.
Skivka LM, Susak YaM, Trompak OO, et al. The effect of monotherapy and combined therapy with NSC-631570 (Ukrain) on growth of low-and high-metastasizing B16 melanoma in mice. J Oncol Pharm Pract 2011; 17: 339-49. http://dx.doi.org/10.1177/1078155210382470
Vega-Avila E, Pugsley MK. An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. Proc West Pharmacol Soc 2011; 54: 10-14.
Zhang N, Kong X, Yan Sh, et al. Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci 2010; 101: 2375-83. http://dx.doi.org/10.1111/j.1349-7006.2010.01680.x
Zhang X, Xu L, Qiang Yu. Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth. Mol Cancer 2010; 9: 1-11. http://dx.doi.org/10.1186/1476-4598-9-7
Hamburger AW, Lurie KA, Condon ME. Stimulation of anchorage-independent growth of human tumor cells by interleukin 1. Cancer res 1987; 47: 5612-15.
Gluzman DF, Abramenko IV, Skliarenko LM, et al. Diagnosis of leukemia. Atlas and practical guide. Kiev: Morion 2000.
Detre S, Saccani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. Clin Pathol 1995; 48: 876-78. http://dx.doi.org/10.1136/jcp.48.9.876
Kameron IL, Pool TB, et al. The Transformed Cell. New York: Academic Press 1981.
Vorontsova AL, Kudryavets YuI, Fadeev VA, et al. Antimetastatic action of interferon in the surgical removal of experimental tumours. Exp Oncol 1983; 5: 45-9.
Silletti S, Yao JP, Pienta KJ, et al. Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. Int J Cancer 1995; 63: 100-5. http://dx.doi.org/10.1002/ijc.2910630118
Madeja Z, Szymkiewicz I, Zaczek A, et al. Contact-activated migration of melanoma B16 and sarcoma XC cells. Biochem Cell Biol 2001; 79: 425-40. http://dx.doi.org/10.1139/o01-029
Wieser RJ, Renauer D, Schafer A, et al. Growth control in mammalian cells by cell-cell contacts. Envir Health Persp 1990; 88: 251-53. http://dx.doi.org/10.1289/ehp.9088251
Liang Ch, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2: 329-33. http://dx.doi.org/10.1038/nprot.2007.30
Tsurimoto T. PCNA binding proteins. Front Biosci 1999; 4: 849-58. http://dx.doi.org/10.2741/Tsurimoto
Caramel J, Papadogeorgakis E, Hill L, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 2013; 24: 466-80. http://dx.doi.org/10.1016/j.ccr.2013.08.018
Lin K, Baritaki S, Militello L, et al. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-?B/Snail/RKIP/PTEN circuit. Genes Cancer 2010; 1: 409-20. http://dx.doi.org/10.1177/1947601910373795
Kim JE, Leung E, Baguley BC, et al. Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines. Front Genet 2013; 4: 1-8. http://dx.doi.org/10.3389/fgene.2013.00097
Bonitsis N, Batistatou A, Karantima S, et al. The role of cadherin/catenin complex in malignant melanoma. Exp Oncol 2006; 28: 187-93.
Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 2005; 10: 153-63. http://dx.doi.org/10.1111/j.1087-0024.2005.200407.x
Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-85. http://dx.doi.org/10.1083/jcb.113.1.173
Hotz B, Arndt M, Dullat S, et al. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 2007; 13: 4769-76. http://dx.doi.org/10.1158/1078-0432.CCR-06-2926
Bolos V, Peinao H, Perez-Moreno MA, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003; 116: 499-511. http://dx.doi.org/10.1242/jcs.00224
Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 2004; 48: 365-75. http://dx.doi.org/10.1387/ijdb.041794hp
Vernon AE, LaBonne C. Tumor metastasis: A new Twist on epithelial mesenchymal transitions. Curr Biol 2004; 14: R719-21. http://dx.doi.org/10.1016/j.cub.2004.08.048
Aoyagi S, Hata H, Homma E, et al. Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study. Oncology 2012; 82: 139-46. http://dx.doi.org/10.1159/000336490
Inman JL, Russell GB, Savage P, et al. Low-dose adjuvant interferon for stage III malignant melanoma. Am Surg 2003; 69: 127-30.
Beiteke U, Ruppert P, Garbe C, et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls. Hautarzt 1993; 44: 365-71.
